Cronos Group Inc. (CRON) Fair Value 2026

CRON · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.4 /10

32 fundamental signals · 7 models active

Value Trap Risk

SAFE (12/100)

Quick Summary — As of 2026-08-28, Cronos Group Inc. (CRON) trades at $3.38, versus a $1.20 median fair value across its 7 active models — 64.4% below the current price. QOC: 7.4/10. Value Trap Risk: 12/100 (SAFE). 7/13 models active. Within that set, the Bayesian DCF component alone returns $1.13.

Key Facts

Ticker
CRON
Price
$3.38
Quality Score
7.4/10
Value Trap Risk
12/100
Models Active
7/13
Last Updated
Strength: 7 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Cronos Group Inc. (CRON) Undervalued or Overvalued in 2026?

According to CirclFi’s 7-model valuation engine, Cronos Group Inc. (CRON) appears overvalued as of : the median of 7 independent fair value estimates is $1.20, 64.4% below the current price of $3.38. Estimates range from $0.99 to $2.31. CRON scores 7.4/10 on fundamental quality and 12/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. CRON’s -64.4% gap is wider than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -8.3%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Cronos Group Inc. Stock in 2026? →

What Fair Value Does Each Model Give CRON?

7 Intrinsic Value Models vs. Current Price ($3.38)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $1.13 -66.5%
Ensemble · Medium Conviction
 $1.20 -64.4%
Scenario · High Conviction
 $0.99 -70.7%
Unlock the Full Matrix

Access 4 additional models including ML-RIV, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 7 Models →

Cancel anytime · No contracts · Instant access

What Is CRON's Fair Value Range?

Spread across 7 independent models · $0.99 to $2.31

CirclFi's 7 active models place Cronos Group Inc. (CRON) between $0.99 and $2.31 per share, a spread of 110% of the median. The median of that range — $1.20 — is the fair value CirclFi publishes for CRON, against a current price of $3.38.

Low · First ChicagoHigh · FTNN
$0.99median $1.20$2.31
Where the range comes from
Most bearish modelFirst Chicago$0.99
Most bullish modelFTNN Topology$2.31
Model agreement0 bullish · 7 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for CRON. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on CRON, not a CirclFi price target. How each model works →

What Is Cronos Group Inc. (CRON) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Cronos Group Inc.'s intrinsic value is estimated at $1.20. Trading at its current price of $3.38, the valuation engine raises significant caution: 7 of 7 models flag downside risk, projecting a median implied return of -64.4%. The most optimistic model, FTNN, places fair value at $2.31 (-31.5%), while First Chicago — the most conservative — estimates $0.99 (-70.7%). This +39.2% gap reflects genuine analytical uncertainty about Cronos Group Inc.'s intrinsic worth.

What Do the Models Say About CRON?

7 of 13 models are currently active for CRON. All 7 active models suggest the stock trades above fair value. Taken together, their median fair value for CRON is $1.20 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $1.13 on its own, implying -66.5% downside from the current price. See which stocks rank higher →

How Does CRON Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, CRON ranks #23 by Quality of Company score. CirclFi's QOC score of 7.4/10 evaluates 32 fundamental signals. A score of 7.4 indicates above-average quality.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

The Drug Manufacturers - Specialty & Generic sector introduces analytical considerations specific to pharmaceutical industry businesses. For Cronos Group Inc., metrics like revenue per drug provide important context that general-purpose valuation models may underweight.

Is CRON a Value Trap?

CirclFi's Value Trap algorithm assigns CRON a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

7 of 13 models are active for Cronos Group Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Cronos Group Inc. scores 7.4 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +39.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CRON valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CRON's 7 active models, average confidence is 46%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Cronos Group Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

PCRXPacira BioSciences, Inc.QOC 7.8TRLVTrulieve Cannabis Corp.QOC 7.3HIMSHims & Hers Health, Inc.QOC 7.9SUPNSupernus Pharmaceuticals, Inc.QOC 7.2XERSXeris Biopharma Holdings, Inc.QOC 7.9ELANElanco Animal Health IncorporatedQOC 7.2AYTUAytu BioPharma, Inc.QOC 6.1CANNTrees CorporationQOC 5.1HCMHUTCHMED (China) LimitedQOC 2.7UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: PCRX · TRLV · HIMS · SUPN · XERS · ELAN · AYTU · CANN · HCM · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to CRON?

7 companies across all industries closest to CRON’s Quality of Company score of 7.4/10.

CXTCrane NXT, Co.QOC 7.4USFDUS Foods Holding Corp.QOC 7.4MSGMMotorsport Games Inc.QOC 7.4CXWCoreCivic, Inc.QOC 7.4AVAAvista CorporationQOC 7.4LAZLazard, Inc.QOC 7.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CXT · USFD · MSGM · CXW · AVA · LAZ · NVDA

Where Does CRON Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

CRON is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Cronos Group Inc.’s Valuation?

What is Cronos Group Inc.'s intrinsic value in 2026?

CirclFi puts Cronos Group Inc. (CRON)'s intrinsic value at $1.20 — the median of 7 independent model estimates as of 2026-08-28, ranging from $0.99 to $2.31. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $1.13 on its own. The Quality of Company score is 7.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CRON overvalued or undervalued right now?

At $3.38, 0 of 7 active models suggest CRON may be undervalued, while 7 indicate potential overvaluation. The median of all 7 fair value estimates is $1.20, 64.4% below the current price of $3.38 — a consensus view that CRON is overvalued. The assessment depends on which methodology best fits Cronos Group Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 7.4 mean for CRON?

Cronos Group Inc.'s QOC of 7.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on CRON?

CirclFi analyzes CRON with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 7 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on CRON?

Of the 7 models currently active on CRON, FTNN Topology is the most bullish at $2.31 per share, and First Chicago is the most bearish at $0.99. CirclFi's published fair value for CRON is the median of that range, $1.20, not either extreme. The gap between the two ends equals 110% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is CRON a value trap in 2026?

Cronos Group Inc.'s Value Trap score is 12/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 7-model valuation engine, Cronos Group Inc. (CRON) has a median fair value of $1.20 — 64.4% below the current price of $3.38 — as of 2026-08-28.” Source: circlfi.com/stock/CRON/ · Methodology
Primary sources for this CRON valuation
  • Financial statements: Cronos Group Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001656472) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CRON as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 7 mathematical frameworks give you clarity on CRON.

Unlock All 7 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

4 models hidden for CRON Unlock All 7 — $39/mo